tiprankstipranks
Advertisement
Advertisement

ASND Stock Latest News

Wedbush sees BioCryst, Ascendis as potential next targets after Crinetics deal
The FlyWedbush sees BioCryst, Ascendis as potential next targets after Crinetics deal
4d ago
ASND
BCRX
Ascendis Pharma price target raised to $280 from $275 at RBC Capital
PremiumThe Fly
Ascendis Pharma price target raised to $280 from $275 at RBC Capital
4d ago
ASND
Ascendis Pharma Unveils Two-Year Pivotal Trial Data for TransCon CNP in Children With Achondroplasia
PremiumCompany Announcements
Ascendis Pharma Unveils Two-Year Pivotal Trial Data for TransCon CNP in Children With Achondroplasia
11d ago
6K
ASND
Ascendis Pharma reports new radiographic data from Week 104 from ApproaCH Trial
PremiumThe Fly
Ascendis Pharma reports new radiographic data from Week 104 from ApproaCH Trial
11d ago
ASND
Ascendis Pharma Closes Warrant Exercise Window, Expands Share Capital
PremiumCompany Announcements
Ascendis Pharma Closes Warrant Exercise Window, Expands Share Capital
12d ago
6K
ASND
Ascendis Pharma added to multiple Russell U.S. Indexes
PremiumThe FlyAscendis Pharma added to multiple Russell U.S. Indexes
15d ago
ASND
Ascendis Pharma Monetizes FDA Priority Review Voucher for $187.5 Million
Premium
Company Announcements
Ascendis Pharma Monetizes FDA Priority Review Voucher for $187.5 Million
24d ago
6K
ASND
Ascendis Pharma Posts Strong 3.5-Year Phase 3 Data for TransCon PTH in Hypoparathyroidism
Premium
Company Announcements
Ascendis Pharma Posts Strong 3.5-Year Phase 3 Data for TransCon PTH in Hypoparathyroidism
26d ago
6K
ASND
Ascendis Pharma completes Phase 3 PaTHway Trial
PremiumThe Fly
Ascendis Pharma completes Phase 3 PaTHway Trial
27d ago
ASND
Ascendis Pharma Reports Five-Year TransCon PTH Data Showing Sustained Benefits in Hypoparathyroidism
PremiumCompany Announcements
Ascendis Pharma Reports Five-Year TransCon PTH Data Showing Sustained Benefits in Hypoparathyroidism
29d ago
6K
ASND
Ascendis Pharma announces five-year data from PaTH Forward Trial
PremiumThe Fly
Ascendis Pharma announces five-year data from PaTH Forward Trial
30d ago
ASND
Ascendis Pharma Grants New Employee Warrants as Part of Updated Equity Incentive Plan
PremiumCompany Announcements
Ascendis Pharma Grants New Employee Warrants as Part of Updated Equity Incentive Plan
1M ago
6K
ASND
Ascendis Pharma ‘oversold’ following ITC development, says Oppenheimer
PremiumThe FlyAscendis Pharma ‘oversold’ following ITC development, says Oppenheimer
1M ago
ASND
BMRN
Analyst Reiterates Buy on Ascendis Pharma, Keeps $288 Price Target Amid ITC Uncertainty and Strong Yorvipath Rollout
Premium
Ratings
Analyst Reiterates Buy on Ascendis Pharma, Keeps $288 Price Target Amid ITC Uncertainty and Strong Yorvipath Rollout
1M ago
ASND
StubHub, Jazz Pharmaceuticals upgraded: Wall Street’s top analyst calls
Premium
The Fly
StubHub, Jazz Pharmaceuticals upgraded: Wall Street’s top analyst calls
2M ago
AMT
BAP
Ascendis Pharma initiated with a Buy at Citi
PremiumThe Fly
Ascendis Pharma initiated with a Buy at Citi
2M ago
ASND
Ascendis Pharma price target raised to $329 from $324 at Evercore ISI
PremiumThe Fly
Ascendis Pharma price target raised to $329 from $324 at Evercore ISI
2M ago
ASND
Ascendis Pharma Issues New Employee Warrants, Keeps Large Pool Available for Future Grants
PremiumCompany Announcements
Ascendis Pharma Issues New Employee Warrants, Keeps Large Pool Available for Future Grants
2M ago
6K
ASND
Ascendis Pharma price target raised to $345 from $342 at Barclays
PremiumThe Fly
Ascendis Pharma price target raised to $345 from $342 at Barclays
2M ago
ASND
Ascendis Pharma Earnings Call Highlights Growth Momentum
PremiumCompany AnnouncementsAscendis Pharma Earnings Call Highlights Growth Momentum
2M ago
ASND
Ascendis Pharma price target lowered to $326 from $330 at Wells Fargo
Premium
The Fly
Ascendis Pharma price target lowered to $326 from $330 at Wells Fargo
2M ago
ASND
Analyst Reiterates Buy on Robust Rare Endocrine Portfolio and Pipeline Progress as Price Target Nudged to $288 on Higher Share Count
Premium
Ratings
Analyst Reiterates Buy on Robust Rare Endocrine Portfolio and Pipeline Progress as Price Target Nudged to $288 on Higher Share Count
2M ago
ASND

Trending

Name
Price
Price Change
SPX
S&P 500
―
DJIA
Dow Jones
―
NDX
Nasdaq 100
―
More Trending Stocks >